Table 1.
Median length of the hazard period and (relative) frequency of the individuals across clinical cohort levels
| Lifetime survival (n = 287)1 |
Overall survival (n = 287)2 |
Progression-free survival (n = 284) 2 |
||||
|---|---|---|---|---|---|---|
| Censored | (0.12) | (0.12) | (0.23) | |||
| Lifetime | 59.2 | 13.1 | 6.5 | |||
| Gender | ||||||
| Male | 58.8 | (0.63) | 13.6 | (0.63) | 6.6 | (0.63) |
| Female | 61.1 | (0.37) | 12.1 | (0.37) | 6.4 | (0.37) |
| Race | ||||||
| White | 59.7 | (0.77) | 13.1 | (0.77) | 6.8 | (0.77) |
| Other | 57.7 | (0.23) | 12.6 | (0.23) | 5.3 | (0.23) |
| Therapy | ||||||
| CRnoT | 57.7 | (0.40) | 15.7 | (0.40) | 8.0 | (0.34) |
| R | 60.7 | (0.35) | 12.3 | (0.35) | 5.3 | (0.41) |
| CRT | 53.4 | (0.10) | 15.4 | (0.10) | 6.8 | (0.10) |
| Other | 64.8 | (0.08) | 14.2 | (0.08) | 7.9 | (0.08) |
| None | 70.5 | (0.07) | 2.9 | (0.07) | 1.4 | (0.07) |
| ProgRec | ||||||
| Yes | 57.6 | (0.77) | 15.1 | (0.77) | - | (0.77) |
| No | 64.8 | (0.23) | 5.9 | (0.23) | - | (0.23) |
1 expressed in years;
2 expressed in months.